Horizon Kinetics’s Indaptus Therapeutics INDP Stock Holding History

Horizon Kinetics’s Portfolio INDP Stock Details INDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$413K	Hold	24	–	–	0.01%	261
2018 Q3	$310K	Hold	24	–	–	0.01%	421
2018 Q2	$241K	Buy	24 +9	+60%	+$99.8K	0.01%	449
2018 Q1	$211K	Buy	+15	New	+$213K	0.01%	457

Other funds holding INDP

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Horizon Kinetics's INDP Position: Q4 2018 in Review

Horizon Kinetics held its Indaptus Therapeutics (INDP) position steady in Q4 2018 at 24 shares worth $413K. The position accounts for 0.01% of the portfolio, ranked #261.

Horizon Kinetics first reported a position in INDP in Q1 2018 and has held it in 4 quarters since. 30 funds tracked by Wall St. Rank hold INDP as of Q4 2018.

Horizon Kinetics held 24 shares of Indaptus Therapeutics worth $413K as of Q4 2018.
Horizon Kinetics left its Indaptus Therapeutics share count unchanged in Q4 2018.
Indaptus Therapeutics made up 0.01% of Horizon Kinetics's portfolio in Q4 2018, its #261 holding.
Horizon Kinetics first reported a position in Indaptus Therapeutics in Q1 2018 and has held it in 4 quarters since.
30 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q4 2018.

Based on Horizon Kinetics's 13F filing for Q4 2018, filed 14 Feb 2019.